Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy.
EGFR
EGFR/HER2 heterodimers
HER2
absolute quantification
breast cancer
cancer cell heterogeneity
correlative light- and liquid-phase electron microscopy
gastric cancer
single molecule detection
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
19 11 2021
19 11 2021
Historique:
received:
12
10
2021
revised:
10
11
2021
accepted:
15
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Currently, breast cancer patients are classified uniquely according to the expression level of hormone receptors, and human epidermal growth factor receptor 2 (HER2). This coarse classification is insufficient to capture the phenotypic complexity and heterogeneity of the disease. A methodology was developed for absolute quantification of receptor surface density
Identifiants
pubmed: 34831465
pii: cells10113244
doi: 10.3390/cells10113244
pmc: PMC8623301
pii:
doi:
Substances chimiques
EGFR protein, human
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1027-C7
Organisme : Else Kröner-Fresenius-Stiftung
ID : Investigation of the Influence of Breast Cancer Drugs on HER2 Dimerization at the Molecular Level in Individual Cells Aiming to Find Clues for Causes of Drug Resistance: HERe
Références
Antibodies (Basel). 2020 Jul 20;9(3):
pubmed: 32698317
J Vis Exp. 2020 Sep 21;(163):
pubmed: 33016942
J Biol Chem. 2004 Jan 16;279(3):1713-9
pubmed: 14593113
Methods. 2008 Jul;45(3):227-32
pubmed: 18620061
Antibodies (Basel). 2019 Dec 04;8(4):
pubmed: 31817205
Elife. 2013 Jul 16;2:e00708
pubmed: 23878723
Cell. 2013 Jan 31;152(3):557-69
pubmed: 23374350
Onco Targets Ther. 2014 Dec 16;8:7-14
pubmed: 25565860
Sci Adv. 2015 Jul 17;1(6):e1500165
pubmed: 26601217
Cancer Metastasis Rev. 2015 Mar;34(1):157-64
pubmed: 25712293
Front Pharmacol. 2015 Nov 24;6:283
pubmed: 26635612
Front Immunol. 2013 Dec 06;4:427
pubmed: 24367367
Cancer Res. 1984 Jun;44(6):2259-65
pubmed: 6372991
Biomedicines. 2021 Jun 28;9(7):
pubmed: 34203351
Front Cell Dev Biol. 2016 Aug 22;4:88
pubmed: 27597943
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Am J Pathol. 2013 Nov;183(5):1446-1460
pubmed: 24035511
Nano Lett. 2020 Nov 11;20(11):7948-7955
pubmed: 33034459
J Cell Sci. 2008 Oct 1;121(Pt 19):3207-17
pubmed: 18782861
Cells. 2019 Apr 05;8(4):
pubmed: 30959819
Br J Cancer. 2014 Sep 9;111(6):1065-71
pubmed: 25117817
J Histochem Cytochem. 1978 Aug;26(8):618-21
pubmed: 357645
Annu Rev Pathol. 2013 Jan 24;8:277-302
pubmed: 23092187
EMBO J. 1996 May 15;15(10):2452-67
pubmed: 8665853
Histochem Cell Biol. 2015 Aug;144(2):123-31
pubmed: 26138928
Clin Pharmacokinet. 2019 Feb;58(2):169-187
pubmed: 29802542
Proteomics. 2011 May;11(10):2063-70
pubmed: 21480528
Cell Rep. 2019 Nov 19;29(8):2164-2174.e5
pubmed: 31747591
Cell. 2015 Jan 15;160(1-2):145-60
pubmed: 25594178
J Biol Chem. 2012 Sep 7;287(37):31116-25
pubmed: 22822073
Cytometry. 1996 Nov 1;25(3):271-9
pubmed: 8914824
Front Oncol. 2019 Aug 23;9:800
pubmed: 31508364
Mol Biol Cell. 2017 Aug 9;:
pubmed: 28794264
Cancer Res. 1996 Aug 15;56(16):3823-30
pubmed: 8706030
J Clin Oncol. 2005 Feb 20;23(6):1152-60
pubmed: 15718311
Int J Mol Sci. 2020 Feb 15;21(4):
pubmed: 32075258
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33260837
PLoS One. 2017 Apr 3;12(4):e0174849
pubmed: 28369073
Int J Proteomics. 2014;2014:147648
pubmed: 24693427
J Mol Biol. 2001 Aug 31;311(5):1011-26
pubmed: 11531336
Biophys J. 2018 Feb 6;114(3):688-700
pubmed: 29414714
PLoS One. 2011;6(9):e24739
pubmed: 21931838
J Cell Sci. 2020 Jan 3;133(1):
pubmed: 31822631
Cell. 2013 Jan 31;152(3):543-56
pubmed: 23374349
Virchows Arch. 2021 Jul;479(1):13-21
pubmed: 33496805
Front Genet. 2020 Nov 30;11:604528
pubmed: 33329751
Mol Biol Cell. 2004 Apr;15(4):1557-67
pubmed: 14742716
J Clin Oncol. 2010 Mar 10;28(8):1301-7
pubmed: 20142587
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Mol Med. 2019 Aug 28;25(1):42
pubmed: 31455202
J Biol Chem. 2017 Mar 31;292(13):5291-5310
pubmed: 28188294
Oncogene. 2009 Aug;28 Suppl 1:S32-7
pubmed: 19680294
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Nat Commun. 2016 Sep 07;7:12742
pubmed: 27599456
Nat Neurosci. 2013 Jul;16(7):798-804
pubmed: 23799472
Nanoscale. 2015 Feb 14;7(6):2511-9
pubmed: 25569174
Mol Cell Proteomics. 2020 Apr;19(4):608-623
pubmed: 32051232
J Biol Chem. 1999 Mar 26;274(13):8865-74
pubmed: 10085130
Cancer Commun (Lond). 2020 Jan;40(1):43-59
pubmed: 32067422
Sci Rep. 2013;3:2626
pubmed: 24022088
J Vis Exp. 2015 Sep 11;(103):
pubmed: 26383083
Cancer Discov. 2021 Oct;11(10):2474-2487
pubmed: 33941592
Front Bioeng Biotechnol. 2019 Aug 05;7:187
pubmed: 31448270
Biomark Res. 2019 Oct 31;7:23
pubmed: 31695915
J Cell Biol. 2007 Oct 22;179(2):341-56
pubmed: 17938246
Cancers (Basel). 2020 Dec 03;12(12):
pubmed: 33287297
World J Clin Cases. 2019 Aug 6;7(15):1964-1977
pubmed: 31423428
Front Oncol. 2013 May 21;3:129
pubmed: 23734345
J Phys D Appl Phys. 2018 Nov 7;51(44):443001
pubmed: 30799880
Sci Data. 2021 Apr 23;8(1):115
pubmed: 33893311
Nature. 2006 Nov 30;444(7119):643-6
pubmed: 17122776
Nat Rev Cancer. 2012 May 24;12(6):387-400
pubmed: 22622641
Mol Biol Cell. 2007 Jun;18(6):2112-22
pubmed: 17392511